Introduction
Naphthalimide and bisnaphthalimide are groups of aromatic compounds that have generated intense interests for a number of years by scientists around the world and this is due to their diverse applications in the medical and environmental sciences [1] [2] [3] . For example due to their inherent intense UV and fluorescence properties, the naphthalimido derivatives had been developed as highly selective fluoride ion sensors [4] , molecular probes [5] and dyes [6] . However, the main application to date for the naphthalimides, is their potential as therapeutic agents [7] especially in the area of cancer therapy. The flat aromatic structural of the naphthalimido ring and its ability to bind to DNA by intercalation are attractive features that had attracted much attention in the development of new mono naphthalimides [8] [9] and bisnaphthalimido [10] [11] derivatives for enhanced anticancer activities and aqueous solubility. Among the mononaphthalimido derivatives, Mitonafide and analogues had reached clinical trial but failed to progress due to unpredicted neurological toxicity side effects [12] . The first generation of mononaphthalmides developed by Brana et al. had a short linker chain from the naphthalimido ring with a tertiary amino group [1] . Since then other workers have made many changes to the naphthalimido rings especially with substitution at positions 5 and 6. More recently Qian et al. have been working on 6 substituted naphthalimido derivatives and demonstrated that these compounds exhibited their toxicities due to a multi targets approach that involve inhibition of topoisomerase II and induction lysosomal membrane permeabilization leading eventually to apoptosis and cell death [13] . Here in this work we have focused our attention in the length of linker chains and the terminal groups. The linker alkyl chain was modified with 2, 3 and 4 carbons and the terminal groups include amino, imino, pyrrole, nitrobenzene, ureas. These compounds were screened against breast cancer MCF-7, colon cancer HCT-15 and pancreatic cancer BxPC-3 cell lines.
Results and Discussion
Chemistry 1,8-Naphtalimide compounds bearing 2,3 and 4 carbon chains, and different terminal functional groups were synthesized by methodologies based on well-established chemistry. Scheme 1 depicts the synthesis of naphthlimido alkylamine and alkyl alcohol products 1a-f in excellent yields. This was achieved by the reaction of naphthalic anhydride with corresponding diamines and amino alcohols in excess [14] .
Biological activity
Toxicity of the compounds to tumor cells: All the naphthalimido compounds described above were firstly screened for activity in a human breast tumor cell line (MDA-MB-231) at concentrations range of 0-40 µM using the MTT assay (data not shown). Compounds that presented potential as anticancer agents were further analyzed by the sulforhodamine B assay on three human tumor cell lines: MCF-7 (breast cancer), HCT-15 (colon cancer) and BxPC-3 (pancreatic cancer). Results are presented in (Table 1 ). The GI 50 values were determined for the most active compounds, i.e. those showing ≥ 50% of cell growth inhibition in 5 µM concentration ( Table 2 ). The breast cancer cell line MCF-7 showed to be more sensitive to the naphthalimidoethylamine 1a (GI 50 of 4.23 ± 0.50 µM), and to the urea 6f, which presented the lowest GI 50 of all compounds tested (2.44 ± 0.25 µM). Concerning the other tumor cell lines HCT-15 and BxPC-3, the triazolo compound 9d (scheme 3) was the most active against HCT-15 (GI 50 of 3.60 ± 0.25 µM), whereas the guanidine compound 4a (scheme 2) was the most potent against BxPC-3. GI 50 of compound 4a was not determined due to solubility limitation, but a 42.4 ± 1.6 % of cell growth inhibition in the presence of 5 µM of the compound suggested a GI 50 value slightly over 5 µM. Results show means ± SE of at least three independent experiments performed in duplicate. NA: no activity shown. Structureactivity relationship of the compounds against the three tumor cell lines showed that generally compounds with a 2 carbon linker (n=2) provided the best inhibition. The simplest compound, amine 1a inhibited MCF-7 cell growth in a higher extend (62.4 ± 4.4 %), followed by triazole 9d (46.5 ± 5.9 % inhibition), imine 2c (45.5 ± 12.1 % inhibition), guanidine 4a (29.0 ± 1.4 % inhibition), and urea 6d (14.0 ± 5.9 % inhibition). In addition, the activity of 1a compound was lost when increasing the chain length from 2 to 3 carbon atoms (1b with 19.9 ± 3.3 % inhibition), suggesting that the shorter carbon chain (n=2) increase the effect of amine type 1 compounds against the MCF-7 cell line. For the colon cancer HCT-15 cell line, compound 9d bearing a 4-phenyl-1H-1,2,3-triazole unit showed higher activity (64.9 ± 7.7 % inhibition) than any other 2 carbon-atoms linker compounds. Again, the cellular growth inhibition was lost when the triazole group was combined with a 3 atoms carbon chain; inhibition with 9e is only 8.2 ± 8.0 %. In the pancreatic cancer BxPC-3 cell line, the guanidine compound 4a showed to be the most active compound with 42.4 ± 1.6 % cell growth inhibition. Within the three types of tumor cell lines tested, BxPC-3 turned out to be the most sensitive to the compound 4a. Interestingly a different trend was observed with the ureas, in particular compound bearing a p-nitrophenyl group. Urea 6f bearing a 4 carbon atoms chain showed to be the most active compound against MCF-7 cell line, displaying 84.5 ± 3.2 % inhibition of cellular growth. Shorter carbon chain resulted in the loss of activity particularly on MCF-7 cell line; this is evident when comparing the inhibition activity of compounds 6f with 6e (n=3; 28.3 ± 4.1 %), and 6d (n=2; 14.0 ± 5.9 %). The nature of terminal groups in the urea compounds was also found to be important. This was evident when comparing the inhibitory activity of the three ureas 6f (84.5 ± 3.2 %), 6i (10.8 ± 0.6 %) and 6l (8.6 ± 3.1 %), all possessing 4-carbon atoms chains. Certainly, compound 6i incorporates an extra methylene within the benzyl, extending the length of the compound, but as in the benzyl series (6g, 6h, 6i) the length of the carbon chain does not appear to have a relationship between activity and the structure of the molecules. However the relevant structural feature in terms of activity appears to be related with the presence of the nitro group attached to the phenyl group. a GI 50 , concentration of compound required to cause 50% cell growth inhibition after a continuous exposure for 48h. Results are presented as means ± SE of at least three independent experiments performed in duplicate. ND: not determined. Further analysis of the results obtained from the heterocylic imine compounds revealed that the 2c compound bearing a thiophene unit together with a 2 atom carbon chain presented better activity than its furan and pyrrole counterparts on MCF-7 (45.5 ± 12.1 % inhibition), and HCT-15 (46.2 ± 9.3 % inhibition) cell lines. BxPC3 cell line was more sensitive to the furan compound 2b (33.5 ± 7.8 % inhibition). Compound 2a bearing a pyrrole ring was the least active among the 2 carbon atoms chain imine compounds. The amino compounds in its hydrochloride salts (3f and 3g), obtained from the heterocyclic imines 2f and 2g, showed no activity on any of the analyzed tumor cell lines. For the MCF-7 cell the best inhibitor compound obtained was the compound 6f with a percentage of cell growth inhibition of 84.5% at 5 µM and a GI 50 of 2.44 µM, close to the one found for the reference drug, doxorubicin, with 99.5% and a GI 50 of 0.024 µM. HCT-15 was more susceptible to the compound 9d with 64.9% of cell growth inhibition at 5 µM, and a GI 50 of 3.6 µM, similar to doxorubicin which presented 73.6% and a GI 50 of 1.07 µM. These two compounds can be proposed as leaders for modification by medical chemistry.
Toxicity of the compounds to non-tumor cells:
The toxicity of the synthesized compounds was evaluated on THP-1 differentiated macrophages and compounds 1a, 2c, 6f and 9d were further tested on mouse bone marrow-derived macrophages (BMMØ) by the MTT assay. No toxicity was observed for a 10 µM concentration from most of the compounds on THP1 differentiated macrophages after 72h incubation (data not shown). The exception occurred with compound 6f, which presented 61.1 ± 3.0 % of cell viability, value below the minimum considered as non-toxic in the screening of new compounds (70 %). However, toxicity assays performed on BMMØ with 5 µM and 50 µM compound concentrations revealed no toxicity of compound 6f for any of the concentrations tested (Table 3) . Results are presented as means ± SE of two independent experiments performed in triplicate. This contradictory result may be related with the fact that THP1 differentiated macrophages derived from an immortalized cell line, which although not tumorigenic is derived from the peripheral blood of a patient with acute monocytic leukemia in contrast with the primary non-tumor BMMØ. Also, no toxicity was observed on BMMØ for compounds 1a, 2c and 9d at a concentration of 5 µM. It is noteworthy to mention that at 50 µM concentration, compound 1a induced a decrease in cell viability to 46.2 ± 12.9 % and compound 2c to 67.3 ±
Compound
Inhibition of cell growth (%) 16.6 %. These values suggest some toxicity of these two compounds only at a concentration tenfold higher than the concentration used in our assays (5 µM).
Conclusions
Several naphthalimides were synthetized in good yields and showed very good GI 50 values towards MCF-7, HCT-15, and BxPC-3 cancer cell lines. By changing the alkyl chain length between the naphthalimido group and the functionality at the end of the chain, it was possible to find the best structural features from 1,8-naphthalimido derivatives to achieve enhanced anticancer activity, either generically speaking either against each type of cancer cell line. From these results new perspectives can be drawn to improve the activity of naphthalimides as anticancer agents.
Experimental Chemistry
General: All starting materials were purchased from SigmaAldrich, were of research-grade quality and were used without further purification. Compounds were purified by dry flash chromatography, using silica 60 <0.063 mm and water pump vacuum. TLC plates (silica gel 60 F 254 , Macherey-Nagel) were visualized either at UV lamp or with I 2 . 1 H NMR and 13 C NMR were carried out on a Varian Unity Plus 300 (300 MHz) and Brucker Avance III 400 (400 MHz) spectrometers. Infrared spectra were recorded on a Bomem MB 104. Samples were run as nujol mulls and oils as thin films. MS spectra were recorded on a VG Autospec M. spectrometer. Microanalyses were performed in a LECO-CHNS-932 analyzer. Melting points (m.p.) were determined on a Gallenkamp block and are uncorrected. The synthesis of compounds 1a-c were described before. 9a The yields were improved by increasing the number of equivalents of diamine, and by diminishing the coupling reaction time. Alcohols 1d-f were prepared by analogy to the synthesis reported for N- (3-propanol 
Synthesis of naftalimide precursors with a terminal hydroxyl group, compounds 1d-f
General procedure: To a solution of 1,8-naphthalic anhydride (1.00-2.03 g, 5.05-10.25 mmol), in DMF (12-24 mL) was added the amino-alcohol (10 equiv.) and DBU (1 equiv.). The reaction mixture was stirred in an oil bath at 75°C, for 4-7 h. Dichloromethane (100 mL) was added, the solution washed with water (5x60 mL) and the organic phase, dried over magnesium sulfate, filtered and concentrated in the rotary evaporator to give compounds 1d-f (88-96 %) as pale yellow solids. 
Synthesis of 2-(2-hydroxy-ethyl)-1H-benzo(de)isoquinoline-

Synthesis of imines 2a-i
General procedure: To a solution of 1,8-naphthalimide 1a-c (92-413 mg, 0.38-1.63 mmol) in ethanol (5-12 mL) was added the aldehyde (1-1.2 eq.), and the mixture refluxed for 20 min-7 h. A solid precipitated out at rt or by cooling at -20°C. The solid formed was filtrated, washed with ethanol, to give the respective imine (compounds 2a-i; 61.7-100 %). -pyrrol-2-yl) -pyrrol-2-yl) 2-(4-((thiophen-2-ylmethylene) -2-ylmethyl) 
Synthesis of (E)-2-(2-(((1H-pyrrol-2-yl)methylene)amino)ethyl -1H-benzo[de]isoquinoline-1,3(2H)-dione (2a):
Synthesis of (E)-2-(2-((furan-2-ylmethylene)amino)ethyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (2b):
Synthesis of (E)-2-(2-(((1H-imidazol-2-yl)methylene)amino) ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2d):
Synthesis of (E)-2-(3-(((1H
Synthesis of (E)-2-(3-((furan-2-ylmethylene)amino)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2f)
Synthesis of (E)-2-(2-((thiophen-2-ylmethylene)amino)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2g):
Synthesis of (E)-2-(4-(((1H
Synthesis of (E)-
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Synthesis of 2-(3-((thiophen
Synthesis of guanidine 4a-c
General procedure: To a solution of 1,8-naphthalimide 1a-c (0.13-0.41 g, 0.53-1.63 mmol) in THF (10 mL) was added 2-methylisothiouronium iodide 10 (1.3 equiv.) at r.t. The suspension was refluxed for 3h -6h 30 min. A solid precipitated out from the reaction mixture by cooling at rt. Guanidines 4a-c (74.1-89.2 %) were obtained as white solids. 1-(3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl) a),b) Signals of methylene Hs at C-2 and C-3, are relative to the two conformations (1:3 ratio) of compound 4b, probably resulting from hydrogen bonding. c) Signals for C-1, C-2 and C-3 of the major conformer. 
Synthesis of 1-(2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)guanidine hydroiodide (4a):
Synthesis of
Synthesis of 1-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)guanidine hydroiodide (4c):
Synthesis of amides 5a-l
General procedure: To a solution of compound 1a-c (0.10-0.15 g, 0.37-0.62 mmol) in a solvent (12-15 mL) was added the anhydride (1.1-2.0 equiv.). The reaction mixture refluxed for 1 h-2 h 30 min., concentrated in the rotary evaporator and the resulting oil cooled to -20°C overnight. White, pale yellow, or brownish solids 5a-l was formed, filtered, and eventually recrystallized from ethanol (54-87 %).
Synthesis of N-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)ethyl)acetamide (5a)
Compound 1a (0.15 g, 0.62 mmol); ethanol (14 mL); acetic anhydride (1.1 equiv.); 1 h; white solid 5a (76 %); m. 
Synthesis of N-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)propyl)acetamide (5b)
Compound 1b (0.15 g, 0.59 mmol); ethanol (14 mL); acetic anhydride (1.1 equiv.); 1 h; white solid 5b (81 %); m. N-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H) N-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl) N-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H) 4-((3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl) 4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)butyl)amino)-4-oxobut-2-enoic acid (5i) Compound 1c (0.10 g, 0.37 mmol); ethanol (12 mL); maleic anhydride (1.1 equiv.); 1 h; white solid 5i (54 %); m. 2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl) 4-(1,3-dioxo-1H-benzo (de)isoquinolin-2(3H)-yl) 
Synthesis of
Synthesis of N-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
Synthesis of
Synthesis of (E)-4-((2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)ethyl)amino)-4-oxobut-2-enoic acid (5g):
Synthesis of (E)-
Synthesis of (E)-4-((
Synthesis of 4-((
Synthesis of 4-((3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)propyl)amino)-4-oxobutanoic acid (5k):
Synthesis of 4-((
Synthesis of ureas 6a-l
General procedure: To a solution of compounds 1a-c (0.15-0.26 g, 0.56-0.83 mmol) in dry toluene (8-16 mL). Kept stirring under nitrogen atmosphere in an ice/water bath, was added dropwise the isocyanate (1.0-2.5 equiv.). After addition is complete the reaction mixture was stirred for 1 h at rt, and then refluxed at 130°C in an oil bath for 4-6 h. The reaction mixture was concentrated in the rotary evaporator, refrigerated at -20°C for 20 h to give white, yellow solids as products, which are eventually purified by column chromatography (silica; solvent), 6a-l (55-98 %). (2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H) 1-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)propyl)urea (6b): Compound 1b (0.20 g, (4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl 1-benzyl-3-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl) 
Synthesis of 1-
Synthesis of
Synthesis of 1-
Synthesis of
Synthesis of 1-benzyl-3-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)propyl)urea (6h)
Compound 1b (0.20 g, 0.79 mmol); dry toluene (16 mL 1-butyl-3-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl) 
Synthesis of
Synthesis of compounds 9d-f
Conversion of alcohols 1d-f into bromides 7d-f
General procedure: To a solution of alcohols 1d-f (0.40-0.50 g, 1.49-2.07 mmol) in DCM (8 mL) kept stirring in an ice/water bath was added carbon tetrabromide (1.6 equiv.) and triphenylphosphine (1.6 equiv.). Stirring was prolonged at rt for 12 to 24 h, then concentrated in the rotary evaporator, and the residue purified by column chromatography (silica, DCM:ethanol, 95:5). Products 7d-f were obtained as white or pale yellow solids (89-99 %). 1H-benzo(d,e) 
Synthesis of 2-(2-bromoethyl)-
Conversion of bromides 7d-f into azides 8d-f
General procedure To a solution of compound 7d-7f (0.19-0.20 g, 0.58-0.66 mmol) in dry DMF (3 mL) kept stirring under nitrogen was added sodium azide (3 equiv.). The suspension was stirred at rt for 3 days. Dichloromethane (15 mL) was added and the mixture washed with water (6x10 mL). The combined organic layers were dried over magnesium sulfate, filtered and the solvent evaporated in the rotary evaporator to give products as white or yellow solids 8d-f (81-93 %). 
Synthesis
Synthesis of 2-(4-azidobutyl)-1H-benzo(de)-isoquinoline-
Cycloadditions of the azides 8d-f with phenylacetylene
General procedure: To a solution of compounds 8d-f (0.11-0.28 g, 0.38-1.05 mmol) in DMF (3-4 mL), was added ascorbic acid (0.1 equiv.), copper sulfate (0.01 equiv.) and phenylacetylene (1.3-1.5 equiv.) [16] . The reaction mixture was kept stirring at 80°C in an oil bath for 5-24 h. The reaction mixture was cooled till rt, dichloromethane (15 mL) was added, and the resulting solution washed with water (6x10 mL). The combined organic phases were dried over magnesium sulfate, evaporated in the rotary evaporator to give white or yellow solids. In one case the crude product was purified by column chromatography (silica, solvent) to give compounds 9d-f (53-95 %). 4-phenyl-1H-1,2,3-triazol-1-yl) 3-(4-phenyl-1H-1,2,3-triazol-1-yl) 
Synthesis of 2-(2-(
Synthesis of 2-(
